Indegene

PatientPoint Expands Best-in-Industry Client Strategy, Analytics and Sales Teams

Retrieved on: 
Wednesday, October 25, 2023
Linda, Research, Health, CPG, Physician, Multiple myeloma, Organization, Merck, Multiple Myeloma Research Foundation, Sarli, HCP, DTP, Growth, Enablement, WebMD, Marketing, Genentech, Strategy, DTC, Patient, IQVIA, Wolters Kluwer, Pharmaceutical industry, Indegene

CINCINNATI, Oct. 25, 2023 /PRNewswire/ -- PatientPoint® today announced exciting growth within its client strategy, analytics and sales organizations, further strengthening its best-in-industry team dedicated to amplifying PatientPoint's reach and impact for life sciences and health and wellness brands.

Key Points: 
  • At PatientPoint, Sarli is focused on identifying emerging industry trends, strengthening client engagement and developing case studies to help advance the point-of-care channel.
  • Melanie Spurrier , Vice President, Research and Analytics: Melanie Spurrier brings 20 years of data and analytics and market research expertise to PatientPoint.
  • PatientPoint also continues to expand its Client Sales and Solutions team, recently welcoming these experienced pharmaceutical, health and wellness and media industry sales leaders:
    David Loux , Vice President, Client Solutions: David Loux joins PatientPoint with 15 years of pharmaceutical and healthcare industry sales experience from sales leadership roles at organizations including Indegene, WebMD, Healthcasts and P\S\L Group.
  • "The unrivaled impact PatientPoint delivers to patients, physicians and our client partners starts with our people—and our world-class team is the reason PatientPoint remains the 35-year point-of-care leader," said PatientPoint Chief Client Officer Linda Ruschau.

Life sciences leaders discuss the future of commercialization at Indegene Digital Summit | September 21-22, 2023 | Virtual-only

Retrieved on: 
Thursday, September 14, 2023
MSD, Indegene, The Carlyle Group, Synthetic media, CX, Chief digital officer, Generative, Merck, Management, Online shopping

PRINCETON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the fifth edition of Indegene Digital Summit, the annual flagship event for global life sciences leaders, on September 21 - 22, 2023.

Key Points: 
  • PRINCETON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the fifth edition of Indegene Digital Summit, the annual flagship event for global life sciences leaders, on September 21 - 22, 2023.
  • This exclusive thought leadership virtual event will see thought-provoking strategic discussions pertinent to the commercialization functions of the life sciences value chain.
  • The summit brings a power-packed lineup of thought leaders from within and beyond the life sciences industry on a single platform to exchange views on the future of commercialization.
  • The leaders will discuss the role of technology paradigms such as Generative AI in transforming traditional commercialization models.

Indegene launches Invisage, an AI-enabled hybrid omnichannel sales and marketing platform to improve HCP impact for life sciences companies

Retrieved on: 
Tuesday, August 22, 2023
Organization, LOE, Senior, HCP, InVisage Technologies, Sales, Indegene

PRINCETON, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company today announced the launch of Invisage [in-vis-ij], an AI-enabled proprietary platform to help life sciences organizations optimize their go-to-market model.

Key Points: 
  • PRINCETON, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company today announced the launch of Invisage [in-vis-ij], an AI-enabled proprietary platform to help life sciences organizations optimize their go-to-market model.
  • Invisage helps deliver personalized outcomes to healthcare professionals (HCPs) by leveraging data from over 2 million HCP and more than 200 million HCP interactions.
  • Invisage is an integrated hybrid omnichannel platform that brings together data, AI-driven scientific modeling, and strategic insights to deploy digital campaigns and partner digital channels with a sales force to expand HCP reach and optimize interactions.
  • “We are excited to introduce Invisage to the market and enable life sciences companies to effectively reach HCPs, powered by Indegene’s AI-driven platform and our team of experts,” said Nancy Phelan, Senior Vice President, Omnichannel Activation, Indegene.

Capital IP and Ghost Tree Provide $40MM to Israel-based Women Health focused ConTIPI Medical

Retrieved on: 
Tuesday, June 20, 2023
Surgery, Medical Devices, Women, Consumer, Health, CE, Medicine, Partnership, Pelvic organ prolapse, Marketing, Pharmacovigilance, Partner, Woman, Privacy, Pelvic floor, Acquisition, Provat Lakra, Capital, FDA, POP, Indegene

Capital IP Investment Partners (“Capital IP”) and Ghost Tree Partners, announced they have secured a total of $40MM of structured capital to ConTIPI Medical Ltd (“ConTIPI”), an innovator in the field of providing non-surgical and disposable solutions for women with various pelvic floor disfunctions.

Key Points: 
  • Capital IP Investment Partners (“Capital IP”) and Ghost Tree Partners, announced they have secured a total of $40MM of structured capital to ConTIPI Medical Ltd (“ConTIPI”), an innovator in the field of providing non-surgical and disposable solutions for women with various pelvic floor disfunctions.
  • Capital IP Managing Partner Aron Dantzig, and Ghost Tree Partners Managing Director David Byrne, stated "Capital IP and Ghost Tree Partners are excited and incredibly proud to have provided a unique financing solution for ConTIPI's groundbreaking ProVate device, POP is a prevalent condition affecting millions of women globally.
  • It empowers women to regain crucial control over their medical treatment and conveniently manage it within the comfort and privacy of their own homes.
  • Capital IP and Ghost Tree feel deeply honored to be part of this innovative device, which we firmly believe will have a profoundly positive impact on the lives of women worldwide.”
    Bourne Partners served as the exclusive financial advisor to ConTIPI Medical Ltd.

ASEAN and Japan Digital Advertising in Pharma and Medical Equipment Market Report 2023: Growing Penetration of Mobile Phones and a Surge in Social Media Users Bolsters Sector

Retrieved on: 
Wednesday, May 31, 2023
ASEAN, Dentsu, USD, Ogilvy (agency), Growth, Digital, Social media, Pharmaceutical industry, Pharma, Indegene

The ASEAN & Japan digital advertising in pharma and medical equipment market is estimated to grow at a highest CAGR of 10.85% and 10.68% respectively over the forecast period, i.e., 2023-2035.

Key Points: 
  • The ASEAN & Japan digital advertising in pharma and medical equipment market is estimated to grow at a highest CAGR of 10.85% and 10.68% respectively over the forecast period, i.e., 2023-2035.
  • The growth of the market can be attributed to growing penetration of mobile phones, followed by surge in social media users.
  • The ASEAN and Japan digital advertising in pharma and medical equipment market is segmented into numerous segment, which includes segmentation by ad format, platform, end user.
  • On the basis of region, the ASEAN & Japan digital advertising in pharma and medical equipment market is segmented into Singapore, Indonesia, Thailand, Malaysia, Vietnam, Philippines, Rest of ASEAN.

Indegene expands partnership with ConTIPI Medical Ltd to manage pelvic organ prolapse in women worldwide

Retrieved on: 
Wednesday, May 24, 2023
Tissue, CE, Medicine, Partnership, Pelvic organ prolapse, Failure, Senior, Marketing, Pharmacovigilance, Woman, POP1, HCP, Pelvic floor, Prolapse, US, Provat Lakra, FDA, POP, US FDA, Birth control, Medical device, Pharmaceutical industry, Indegene

ConTIPI Medical’s mission is to help women suffering from Pelvic Organ Prolapse (POP).

Key Points: 
  • ConTIPI Medical’s mission is to help women suffering from Pelvic Organ Prolapse (POP).
  • The US FDA states that POP occurs when the pelvic floor’s tissues and muscles can no longer support its organs which causes a drop or prolapse of the pelvic organs.
  • Approximately 54 million American women over 20 years old suffer from POP1.
  • Bourne Partners served as the exclusive financial advisor to ConTIPI Medical.

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Wednesday, May 10, 2023
Insurance, Research and development, Food, Anxiety, Dextroamphetamine, Overalls, Policy, Calendar, ADHD, NDA, WFIA, G&A, Research, Lincoln Park, Federal Food, Drug, and Cosmetic Act, Buspirone, ATM, CDMO, Attention deficit hyperactivity disorder predominantly inattentive, Patient, Administration, Associate, Adolescence, R, FDA, PTR, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Market, Precision Time Protocol Industry Profile, Safety, Fine chemical, Cryptocurrency, Pharmaceutical industry, Cingulata, Society, Indegene, Wainwright

KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update. Among other highlights, the Company announced it has obtained an additional $3 million of debt financing, successfully completed the transfer of its proprietary PTR™ manufacturing processes to Societal CDMO, Inc. (Societal) and entered into a joint commercialization agreement with Indegene to provide commercial support for CTx-1301 upon approval from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • CTx-1301: Cingulate advanced its clinical program for CTx-1301 on the streamlined approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit the NDA for CTx-1301 in mid-2024 under the Section 505(b)(2) pathway.
  • Cash Position: As of March 31, 2023, Cingulate had $1.7 million in cash and cash equivalents.
  • This decrease in manufacturing expense was slightly offset by an increase in clinical and regulatory costs as we initiated a Phase 3 clinical trial for CTx-1301 in the first quarter of 2023.

Everest Group recognizes Indegene as a Leader in its Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023

Retrieved on: 
Thursday, April 6, 2023
Operation, Marketing, Service, PEAK, United States Commercial Service, Practice, Investment, Health, Risk management, Management, Indegene

PRINCETON, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- Everest Group recognizes Indegene, a digital-first, life sciences commercialization company, as a Leader in its Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023.

Key Points: 
  • PRINCETON, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- Everest Group recognizes Indegene, a digital-first, life sciences commercialization company, as a Leader in its Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023.
  • “The next few years will be dynamic for the life sciences industry due to the interplay of macroeconomic, geopolitical, and regulatory developments.
  • Increased collaboration of life sciences enterprises with service providers will help achieve this differentiation,” said Abhishek A K, Practice Director at Everest Group.
  • Indegene, which counts 19 of the world’s top 20 biopharma companies as clients, was also named a Leader in Everest Group’s Life Sciences Commercial Services Specialists PEAK Matrix® Assessment 2022.

David Stemler joins CultHealth as Chief Creative Officer

Retrieved on: 
Thursday, March 23, 2023
Acceleration, Creativity, HuffPost, Genomics, Marketing, Creative industries, Indegene, Bloc

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- CultHealth, an Indegene company, has appointed David Stemler as Chief Creative Officer.

Key Points: 
  • NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- CultHealth, an Indegene company, has appointed David Stemler as Chief Creative Officer.
  • David will help CultHealth define and shape its creative strategy and direction, and deliver engaging brand campaigns that aim to generate real business outcomes for clients.
  • “David is a creative genius, and I am thrilled to welcome him into the CultHealth family at an exciting time in our growth journey.
  • We will double down on delivering more inspiring and engaging client campaigns.”
    “There is a massive opportunity to help life sciences brands reimagine marketing and consumer engagement,” said David Stemler, Chief Creative Officer, CultHealth.

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Retrieved on: 
Monday, March 13, 2023
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Cingulata, Attention deficit hyperactivity disorder predominantly inattentive, Database, Senior, Adolescence, HCP, Patient, Food, Pharmacovigilance, Precision Time Protocol Industry Profile, ADHD, Physician, Child, FDA, Partnership, Dietary supplement, Pharmaceutical industry, Indegene

KANSAS CITY, Kan. and PRINCETON, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, and Indegene, a digital-first, life sciences commercialization company, today announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Cingulate recently announced the initiation of its first Phase 3 trial for CTx-1301, an adult dose-optimization efficacy and safety study to assess onset and duration, with results expected in the third quarter of 2023.
  • In addition, the Company plans to initiate its pivotal Phase 3 trial, a fixed-dose, placebo-controlled study in pediatric and adolescent patients with ADHD, in mid-2023.
  • “This agreement provides a clear path to commercialize CTx-1301, upon FDA approval, designed specifically to tackle the unmet needs of this $20 billion market by providing the first true, entire-active-day treatment for ADHD.
  • But the clinical success of a potential treatment can only be realized with commercial excellence, making this partnership between Cingulate and Indegene a critical step for our Company,” said Shane J Schaffer, Chairman and CEO, Cingulate.